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Aims Previous studies indicate that ventricular pacing may precipitate heart failure (HF). We investigated occurrence of HF
during long-term follow-up among patients with sick sinus syndrome (SSS) randomized to AAIR or DDDR pacing.
Furthermore, we investigated effects of percentage of ventricular pacing (%VP) and pacing site in the ventricle.
Methods
and results
We analysed data from 1415 patients randomized to AAIR (n ¼ 707) or DDDR pacing (n ¼ 708). Ventricular pacing
leads were recorded as located in either an apical or a non-apical position. The %VP and HF hospitalizations were
recorded during follow-up. Patients were classified with new HF, if in New York Heart Association (NYHA) func-
tional class IV or if presence of ≥2 of: oedema; dyspnoea; NYHA functional class III. Mean follow-up was
5.4+ 2.4 years. Heart failure hospitalizations did not differ between groups. In the AAIR group, 170 of the 707
(26%) patients developed HF vs. 169 of the 708 (26%) patients in the DDDR group, hazard rate ratio (HR) 1.00,
95% confidence interval (CI) 0.79–1.22, P ¼ 0.87. In DDDR patients, 146 of the 512 patients (29%) with ventricular
leads in an apical position developed HF vs. 28 of the 161 patients (17%) with the leads in a non-apical position, HR
0.67, CI 0.45–1.00, P ¼ 0.05. After adjustments this difference was non-significant. The incidence of HF was not asso-
ciated with %VP (P ¼ 0.57).
Conclusion In patients with SSS, HF was not associated with pacing mode, %VP, or ventricular lead localization. This suggests that
DDDR pacing is safe in patients with SSS without precipitating HF.
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Introduction
Patients with sick sinus syndrome (SSS) and bradycardia can be
treated by either a single-lead atrial pacemaker (AAIR) or a dual-
chamber pacemaker (DDDR). Recently, The Danish Multicenter
Randomized trial on single-lead atrial pacing vs. dual-chamber
pacing in sick sinus syndrome (DANPACE) trial comparing AAIR
and DDDR pacing in SSS found no difference in mortality
between the two groups.1
The AAIR pacing preserves a normal contraction pattern similar
to the one seen during sinus rhythm, whereas DDDR pacing may
lead to abnormal contraction patterns in the ventricles.2
In some patients, the abnormal contraction pattern seen during
ventricular (DDDR) pacing may lead to left ventricular remodel-
ling, decreased left ventricular function, and dilatation of the left
atrium.3 –5 Further, there is an association with increased incidence
of atrial fibrillation and heart failure (HF).6 –9
Right ventricular apical pacing has been proposed to precipitate
HF as opposed to septal (right ventricular septal, RVS) and outflow
tract (right ventricular outflow tract, RVOT) pacing.2,10,11 These
studies, however, have generally included only small numbers of
patients, and large randomized trials are yet to prove that a non-
apical pacing site is superior in a clinical context.
Therefore, we examined data from the DANPACE trial with the
aim of determining the effect of DDDR pacing as compared with
AAIR pacing with respect to the development of HF judged by
hospital admissions for HF, symptoms, and medication. Further-
more, in patients randomized to DDDR pacing, we examined
the effect of apical pacing compared with non-apical pacing with
respect to the development of HF.
Methods
Study design
The DANPACE trial has been described previously.1 In brief, the trial
randomly assigned 1415 patients with SSS to AAIR or DDDR pacing.
The criteria for inclusion were: symptomatic bradycardia; documen-
ted sino-atrial block or sinus-arrest with pauses .2 s or sinus brady-
cardia ,40 b.p.m. for .1 min while awake; PR interval ≤0.22 s if
aged 18–70 years or PR interval ≤0.26 s if aged ≥70 years; and
QRS width ,0.12 s.
The main exclusion criteria were: atrio-ventricular block; bundle
branch block; long-standing persistent atrial fibrillation (.12
months); atrial fibrillation with ventricular rate ,40 b.p.m. for
≥1 min or pauses .3 s; a positive test for carotid sinus
hypersensitivity.
Enrollment began in March 1999 and was terminated in June 2008.
Patients were followed until September 2009.
The trial was conducted in accordance with the Helsinki Declaration
and approved by the regional Ethics Committee and the Danish Data
Protection Agency. All patients gave written informed consent before
inclusion.
Implantation and programming of
pacemakers
A bipolar lead was implanted in the right atrium, and in patients rando-
mized to DDDR pacing an additional lead was implanted in the right
ventricle. The position of the ventricular lead was noted in the
frontal fluoroscopy plane as being in either an apical or non-apical
position.
The rate-adaptive function was activated in all pacemakers and pro-
grammed with a lower rate of 60 and an upper rate of 130 b.p.m. In
patients with DDDR pacemakers, the paced atrio-ventricular interval
(AVI) was programmed to 140–220 ms according to a pre-specified
algorithm.1 The maximum tracking rate was individualized and the
mode switch function was activated.
Patient follow-up
Follow-up took place after 3 months and again every year after im-
plantation up to 10 years. Mean follow-up was 5.4+ 2.6 years. At
each planned follow-up visit, a printout was made of the pacemaker
memory data accumulated since the previous resetting of the
memory. The percentage of ventricular pacing (%VP) at each follow-up
was calculated using the number of paced and the number of sensed
beats. Furthermore, information regarding HF: New York Heart Asso-
ciation (NYHA) functional class, presence of oedema, presence of
dyspnoea, and medication was collected. The investigators were asked
to only change the pacing mode from AAIR to DDDR pacing in
cases of high-grade atrio-ventricular block or documented symptomatic
atrio-ventricular block of Wenckebach type.
Definition of heart failure
The primary endpoint was hospitalization with HF as reported diagno-
sis. Furthermore, as a secondary endpoint, patients were classified with
new HF if: (i) they presented in NYHA functional class IV or (ii) if two
or more of the following indicators were present: presence of oedema,
presence of dyspnea, and NYHA functional class III.
Statistical analysis
The time until HF hospitalization and the aforementioned HF indicator
criteria were first met was analysed with Cox proportional hazard
regressions. Only crude analysis is reported for HF hospitalizations
due to the small number of events. Following the lines of the first
reporting from the DANPACE trial, stratified analyses of each of a
number of pre-specified confounders were performed (Figures 3 and
4). Furthermore, an analysis adjusting for main effects including all con-
founders is reported. Pacing modes were compared on an
intention-to-treat basis and reported as hazard rate ratios (HR). Ana-
lysis of ventricular lead positions and %VP were done in patients who
received DDDR pacemakers regardless of initial randomization and
reported analogously to pacemaker-type comparisons.
The potentially non-linear relationship between development of HF
and %VP8 that was indicated by the initial analysis was analysed by
fitting fractional polynomials12 in a Cox regression with %VP being a
time-varying covariate.
Statistical tests were two-tailed, and P, 0.05 was considered signifi-
cant. Stata version 11.2 (StataCorp. 2009. Stata: Release 11. Statistical
Software. College Station, TX, USA: Stata Corp LP) was used.
Results
Population
A total of 1415 patients were included in the analysis. Of these,
708 patients were randomized to receive a ventricular lead in
the DDDR group. Among patients randomized to AAIR pacing,
122 patients (17%) received a ventricular lead at the initial oper-
ation or sometime during follow-up. Baseline characteristics of
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patients in the main trial as well as patients who developed HF
after pacemaker implantation are presented in Tables 1 and 2.
The analysis is based on a total of 7496 follow-up visits in 1392
patients spanning over a period of 5.4+2.6 years.
Heart failure
Pacing mode and heart failure
Hospitalization for HF occurred in 27 patients in the AAIR group
vs. 28 patients in the DDDR group [HR 1.06; 95% confidence
interval (CI) 0.62–1.79, P ¼ 0.84] (Figure 1).
There was no difference in NYHA class at inclusion (Table 1) or
at last follow-up, where the number of patients in class I/II/III/IV
were 341/260/61/4 in the AAIR group vs. 364/231/67/4 in the
DDDR group, P ¼ 0.43. In the AAIR group, 170 patients (26%)
developed new HF during follow-up vs. 169 patients (26%) in
the DDDR group, HR 1.00; 95% CI 0.79–1.22, P ¼ 0.87.
Time-to-event curves for HF are displayed in Figure 2. Hazard
ratios for the development of HF adjusting for different variables
are displayed in Figure 3 (intention-to-treat analysis). The smallest
P values for substrata effect of pacing mode were 0.05, for both
substrata ‘age ≤ 75 years’ HR 0.72; 95% CI 0.53–1.00, and sub-
strata ‘age . 75 years’ HR 1.34; 95% CI 1.00–1.80. All other vari-
ables were non-significant (P . 0.31). A fully adjusted hazard ratio
showed no significant effect of pacing mode (AAIR vs. DDDR) on
the development of HF, HR 1.09; 95% CI 0.88–1.35, P ¼ 0.44.
Both development of clinical HF and hospitalization for HF were
strongly associated with the following baseline characteristics:
older age, reduced left ventricular ejection fraction, previous myo-
cardial infarction (MI), use of diuretics, and higher NYHA class
(Table 2).
Pacing site and ventricular pacing
In patients randomized to DDDR pacing 28 of the 161 patients
(17%) with leads in a non-apical position developed HF during
follow-up as compared with 146 of the 512 patients (29%) with
leads in an apical position, HR 0.67; 95% CI 0.45–1.00, P ¼ 0.05.
A per protocol analysis with hazard ratios for the development
of HF, adjusted for different variables, is displayed in Figure 4. A
fully adjusted hazard ratio showed no significant interaction
between apical or non-apical pacing with respect to the develop-
ment of HF, HR 0.76; 95% CI 0.50–1.14, P ¼ 0.18).
The median percentage of ventricular pacing in the DDDR
group was 85% (interquartile range 34–99%). Figure 5 displays
the hazard ratio for development of HF in relation to different
levels of mean %VP.
No significant association was found between %VP and the
development of HF, fractional polynomial vs. no relationship,
P ¼ 0.57.
Discussion
In the hitherto largest randomized setting, the present study inves-
tigated the impact of pacing mode on the development of HF in
patients with SSS. The main findings of the study were that no sig-
nificant difference was found between AAIR and DDDR pacing.
Furthermore, in patients with a ventricular lead, an apical as com-
pared with a non-apical position was not associated with develop-
ment of HF, nor was %VP.
Heart failure and pacing mode
In recent years, increasing attention has focused on minimizing the
amount of ventricular pacing in pacemaker recipients, especially in
the case of SSS without impaired AV conduction.9 In small trials in
patients with SSS, DDDR pacing was associated with more atrial
fibrillation, increased left atrial diameter, and decreased left ven-
tricular performance as assessed by M-mode and tissue Doppler
echocardiography.3,13,14 However, the impact of DDDR pacing
on the development of HF remains unclear in a broader clinical
setting. With 1415 enrolled patients, the present study is the
first to demonstrate that DDDR pacing has no statistically signifi-
cant impact on the development of HF in SSS as compared with
AAIR pacing. These results probably reflect that the modest
effects on left ventricular function of right ventricular pacing—an
absolute decrease in ejection fraction of 5%5—is tolerated and
rarely causes clinical HF in patients who have a normal systolic
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics of the patients
Characteristic AAIR
(n 5 707)
DDDR
(n5 708)
P value
Female gender, n (%) 472 (67) 441 (62) 0.08
Age, years (mean+ SD) 73.5+11.2 72.4+11.4 0.054
Prior history of atrial
fibrillation, n (%)
303 (43) 318 (45) 0.44
Hypertension, n (%) 241 (34.1) 239 (34) 0.90
Previous myocardial
infarction, n (%)
94 (13) 90(13) 0.74
Left ventricular ejection
fraction reduced (,50%),
n (%)
59 (11) 54 (10) 0.55
Left ventricular end-diastolic
diameter in mm,
mean+ SD
47.7+7.3 47.8+7.3 0.45
Symptoms before pacemaker, n (%)
Syncope 359 (51) 349 (49) 0.58
Dizzy spells 597 (84) 587 (83) 0.44
Heart failure 86 (12) 79 (11) 0.56
≥2 of the above three
symptoms
317 (45) 291 (41) 0.16
Medication at randomization, n (%)
Beta-blocker 159 (23) 132 (19) 0.08
Calcium-channel blocker 137 (19) 142 (20) 0.75
Digoxin 73 (10) 62 (9) 0.32
Angiotensin-converting
enzyme inhibitors
160 (23) 170 (24) 0.53
Diuretics 304 (43.0) 263 (37) 0.03
NYHA class, n (%) 0.33
I 503 (71) 522 (73.9)
II 172 (24) 158 (22.4)
III 29 (4) 24 (3.4)
IV 0 2 (0.3)
SD, standard deviation; NYHA, New York Heart Association.
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function, also on the long term. This is in accordance with prior
findings from the MOST trial.15 The programming of a moderately
prolonged atrio-ventricular interval in the DDDR pacemakers1 re-
ducing the mean %VP and allowing atrial emptying may be import-
ant for the avoidance of HF. Previous studies indicate that DDD
pacing leads to a poor prognosis in patients with severely compro-
mised left ventricular function.7,15 The present study confirms that
there is no correlation between %VP and development of HF and,
additionally, the ventricular pacing site did not influence HF devel-
opment. Baseline characteristics, well known to increase risk of HF
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Baseline characteristics of patients with and without heart failure
Characteristic Hospitalization for HF P value Development of HF P value
Yes (n 5 55) No (n 5 1360) Yes (n5 373) No (n5 1019)
Female gender, n (%) 41 (75) 872 (64) 0.15 281(75) 615 (60) ,0.01
Age, years (mean+ SD) 77.0+9.9 72.8+11.3 ,0.01 75.1+10.2 72.1+11.6 ,0.01
Hypertension, n (%) 12 (22) 468 (34) 0.06 136 (36) 334 (33) 0.20
Previous myocardial infarction, n (%) 14 (25) 170(13) 0.012 61 (16) 116 (11) 0.018
Left ventricular ejection fraction reduced (,50%), n (%)a 16 (29) 97 (7) ,0.01 46 (12) 65 (6) ,0.01
Left ventricular end-diastolic diameter in mm, mean+ SD 47.3+7.1 47.8+10.5 0.69 47.4+8.1 47.9+6.9 0.29
Medication at randomization, n (%)
Beta-blocker 11 (20) 280 (21) 1.00 85 (23) 202 (20) 0.23
Calcium-channel blocker 11 (20) 268 (20) 1.00 77 (21) 196 (19) 0.60
Digoxin 10 (18) 125 (9) 0.04 45 (12) 84 (8) 0.04
Angiotensin-converting enzyme inhibitors 21 (38) 309 (23) 0.01 94 (25) 229 (22) 0.32
Diuretics 34 (62) 533 (39) ,0.01 208 (56) 347 (34) ,0.01
NYHA class, n (%) 0.007 ,0.01
I 29(53) 996 (73) 221 (59) 792 (78)
II 22 (40) 308 (23) 123 (33) 200 (20)
III 4 (7) 49 (4) 28 (8) 23 (2)
IV 0 2 (,1) 1 (,1) 0 (0)
HF, heart failure; SD, standard deviation; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction.
aInformation on LVEF missing in 288 patients.
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(age, hypertension, previous MI, reduced systolic function, and
increased left ventricular end-diastolic diameter), were found to
be associated with both development of clinical HF and HF hospi-
talizations in our trial.
Lead position
It is well established that right ventricular apical pacing may have
acute deleterious effects on left ventricular performance as com-
pared with non-apical lead positions, at least when measured by
imaging modalities,10,14,16 whereas the right ventricular systolic
function may not be affected.11 However, the long-term results
of non-apical pacing are ambiguous. Another option is direct His-
bundle and para-Hisian pacing which may offer superior electrical
and haemodynamic response as compared with apical pacing.17– 19
Indeed, Occhetta et al.18 showed an improvement in NYHA func-
tional class, 6 min walk test, and quality of life after 6 months
of para-Hisian pacing. However, this implantation approach is chal-
lenging, requires electrophysiology mapping, and carries a higher
risk of lead dislodgement.
Others, however, have not been able to find any acute benefit
from pacing from a non-apical vs. an apical position.20 Indeed, docu-
mentation for the clinical benefit of non-apical pacing remains
scarce, especially among patients with preserved left ventricular
function. Most studies are not randomized, include a small number
of patients with relatively short follow-up, and endpoints have
been variable and often not directly related to patient outcome.
In the current study, we show that in patients with SSS and pre-
served AV conduction, treated with DDDR pacemaker, there is no
increased risk of HF with right ventricular leads in either the apical
or the non-apical positions, although a trend towards better
outcome in patients with leads in the non-apical positions was
observed. Thus, our study adds to previous publications, which
could not demonstrate any convincing clinical benefit from select-
ive site pacing, despite obvious haemodynamic advantages. Three
on-going trials randomizing patients to apical or septal pacing
(PROTECT PACE, RASP, and OPTIMISE RV) may clarify a possible
importance of pacing site.21 Still, these trials have left ventricular
ejection fraction as the main endpoint and not ‘harder’ clinical end-
points such as HF, stroke, and death.
Ventricular pacing percentage
From previous studies of the effects of DDDR pacing, it has been
the general opinion that the detrimental effects on left ventricular
performance were proportionate to the percentage of ventricular
pacing (%VP). In the Dual-Chamber and VVI Implantable Defibril-
lator (DAVID) trial, Wilkoff et al.7 found that implantable
cardioverter-defibrillator patients with severely compromised left
ventricular ejection fraction had a poorer outcome with DDDR
pacing with a relatively short AVI as compared with VVI back-up
Baseline
All patients
Age <= 75 years
Age > 75 years
Men
Women
No hypertension treatment
Hypertension treatment
No Diuretic treatment
Diuretic treatment
LVEF < 50%
LVEF >= 50%
No previous MI
Previous MI
PQ interval <= 180 ms
PQ interval > 180 ms
NYHA I
NYHA II-IV
Main effects adjustment
–5 .75
AAIR higher HF risk DDDR higher HF risk
1 1.25 1.5 1.75
variable ES (95% CI)
0.98 (0.79, 1.22) 0.87
0.05
0.05
0.39
0.52
0.34
0.31
0.59
0.41
0.72
0.56
0.82
0.75
0.94
0.96
0.80
0.53
0.44
0.72 (0.53, 1.00)
1.34 (1.01, 1.80)
0.83 (0.53, 1.28)
1.08 (0.85, 1.38)
0.88 (0.67, 1.15)
1.20 (0.84, 1.71)
0.92 (0.67, 1.26)
1.13 (0.84, 1.51)
0.89 (0.46, 1.70)
0.93 (0.72, 1.20)
0.97 (0.77, 1.23)
1.09 (0.63, 1.90)
0.99 (0.74, 1.32)
0.99 (0.71, 1.38)
1.03 (0.79, 1.35)
0.89 (0.63, 1.27)
1.09 (0.88, 1.35)
p-value
Figure 3 In patients randomized to AAIR or DDDR pacing hazard ratios for development of new heart failure are shown for different sub-
groups. Patients were classified with new heart failure, if in New York Heart Association functional class IV or if presence of ≥2 of: oedema,
dyspnea, and New York Heart Association functional class III. A fully adjusted hazard ratio is displayed at the bottom. CI, confidence interval;
LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; ES, effect size (hazard ratio).
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pacing (40 b.p.m.). In the current study, we found no association
between %VP and the risk of developing HF. As opposed to the
trial by Sweeney et al.,22 DDDR pacemakers in the current study
were programmed with a moderately prolonged AVI (140–
220 ms), yet preventing extreme first-degree AV block, which in
itself may cause HF symptoms.
Limitations
Echocardiography was only performed at enrolment in the trial.
Therefore, diagnosis of HF in the present study rests on symptoms
and medication. However, we find it unlikely that our indicators of
HF would not identify patients with moderately to severely
depressed systolic function.
It is well known that when using only one fluoroscopic view,
operators may consider a lead in a septal position, even though
it is in fact placed on the anterior free wall of the right ventricle in-
creasing the risk of dyssynchrony and perforation.23– 25 It was,
however, custom in participating centres to review the lead pos-
ition from the left anterior oblique angle in order to exclude an
overly anterior position. We therefore consider it unlikely that a
large number of patients have leads positioned in the anterior
wall of the right ventricle.
Patients in the present study with ventricular leads were not
randomized to an apical or non-apical position of the lead.
Neither does the study represent a randomized comparison of
the effect of %VP on the development of HF. However, the data
were collected prospectively as part of a large randomized multi-
centre trial and indicate the incidence of HF, adjusted for %VP,
during long-term follow-up.
Baseline
All patients
Age <= 75 years
Age > 75 years
Men
Women
No hypertension treatment
Hypertension treatment
No Diuretic treatment
Diuretic treatment
LVEF < 50%
LVEF >= 50%
No previous MI
Previous MI
PQ interval <= 180 ms
PQ interval > 180 ms
NYHA I
NYHA II-IV
Main effects adjustment
.25 .5 .75
Apical location higher HF risk Non-apical location higher HF risk
1 1.51.25 1.75 2
variable ES (95% CI)
0.67 (0.45, 1.00) 0.05
0.18
0.45
0.50
0.08
0.27
0.08
0.14
0.40
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0.08
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0.25
0.55
0.04
0.07
0.41
0.18
0.66 (0.36, 1.21)
0.81 (0.47, 1.40)
0.77 (0.35, 1.66)
0.65 (0.41, 1.05)
0.75 (0.45, 1.25)
0.54 (0.28, 1.07)
0.63 (0.35, 1.15)
0.79 (0.45, 1.37)
0.56 (0.16, 1.97)
0.65 (0.40, 1.06)
0.68 (0.43, 1.06)
0.57 (0.21, 1.49)
0.85 (0.51, 1.44)
0.48 (0.24, 0.97)
0.62 (0.37, 1.04)
0.76 (0.39, 1.47)
0.76 (0.50, 1.14)
p-value
Figure 4 Per protocol analysis in patients with DDDR pacemaker with either apical or non-apical lead positions. Hazard ratios for develop-
ment of new heart failure are shown for different subgroups. A fully adjusted hazard ratio is displayed at the bottom. CI, confidence interval;
LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; ES, effect size (hazard ratio).
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Figure 5 Hazard ratio for the development of heart failure in
relation to mean %VP. The median percentage of ventricular
pacing in the DDDR group was 85% (interquartile range 34–
99%). No significant association was found between %VP and
the development of heart failure, fractional polynomial vs. no re-
lationship, P ¼ 0.57.
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The initial statistical analysis was performed as a per protocol
analysis meaning that some patients transitioned from the rando-
mized AAIR to DDDR pacing modes due to high-grade AV
block. However, this number of patients is relatively small and
does not offset the results of the analysis.
Conclusion
The present study in a large randomized cohort did not find any
difference in development of HF between AAIR and DDDR
(with moderately prolonged AVI) pacing modes in patients with
SSS. A significant association between HF and right ventricular
pacing site (apical vs. non-apical) disappeared with adjustments
for baseline variables. Further, the study did not find any associ-
ation between %VP and development of HF. These findings
suggest that DDDR pacing is safe in patients with SSS without in-
creasing the risk of HF.
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Ventricular oversensing of an implantable cardioverter-defibrillator during
electroconvulsive therapy
Ignasi Anguera1*, Vero`nica Ga´lvez2, and Xavier Sabate´1
1Electrophysiology and Arrhythmia Unit, Cardiovascular Diseases Group, Bellvitge University Hospital-ICS, L’Hospitalet, Barcelona, Spain and 2Neuroscience Group, Mood
Disorders Clinical and Research Unit, Psychiatry Department, Bellvitge University Hospital-ICS, L’Hospitalet de Llobregat, Spain
* Corresponding author. Tel: +34 93 2607618; fax: +34 93 4210839, Email: ianguera@bellvitgehospital.cat
Electroconvulsive therapy (ECT) is an effective treatment for severe depressive patients even in high-risk cardiac patients, such as
those with an implantable cardioverter-defibrillator (ICD), but current practice guidelines recommend disabling all antitachycardia
therapy before each ECT session. We describe a patient with severe psychotic depression who underwent a series of 70 ECT sessions
without deactivation of the ICD. The figure shows continuous monitoring of the ICD with the programmer without significant
ventricular oversensing. The electrical interference produced minimal noise levels with inappropriate detection of several ventricular
events—asterisks [classified as ventricular sense events, ventricular fibrillation events, and other events classified as noise (VN)]. There
were no detections of inappropriate VF episodes and, therefore, there were no inappropriate discharges during the course of 70 ECT
sessions. The reported case suggests that even though ICD therapies should be temporarily deactivated, the risk of inappropriate
therapy due to ECT seems to be low.
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